

Lifetime Probability of Developing (2019, 2021-2022) or Dying (2021-2023) from Cancer, US

	MALES				FEMALES			
	Developing		Dying		Developing		Dying	
	%	1 in...	%	1 in...	%	1 in...	%	1 in...
All sites^a	39.2	3	17.7	6	38.7	3	16.4	6
Brain & ONS	0.6	159	0.5	203	0.5	194	0.4	244
Breast	0.1	789	<0.1	3,695	13.0	8	2.4	43
Colorectal	4.0	25	1.5	66	3.8	26	1.4	70
Esophagus	0.7	136	0.6	155	0.2	451	0.2	548
Hodgkin lymphoma	0.2	451	<0.1	3,067	0.2	532	<0.1	4,283
Kidney & renal pelvis	2.2	45	0.5	194	1.3	75	0.3	348
Larynx	0.4	228	0.2	623	0.1	944	<0.1	2,482
Leukemia	1.8	56	0.8	125	1.3	77	0.6	167
Liver & intrahepatic bile duct	1.4	71	0.9	105	0.7	141	0.6	178
Lung & bronchus	5.4	19	3.7	27	5.4	19	3.5	29
Melanoma of skin ^b	3.5	28	0.4	263	2.6	39	0.2	484
Myeloma	0.9	110	0.4	261	0.7	134	0.3	307
Non-Hodgkin lymphoma	2.2	46	0.7	150	1.8	55	0.5	191
Oral cavity & pharynx	1.6	62	0.4	237	0.7	138	0.2	522
Ovary	--	--	--	--	1.1	90	0.7	141
Pancreas	1.6	61	1.3	75	1.6	61	1.3	75
Prostate	12.9	8	2.2	46	--	--	--	--
Stomach	0.9	106	0.3	290	0.7	145	0.2	405
Testis	0.4	245	<0.1	4,379	--	--	--	--
Thyroid	0.6	162	0.1	1,840	1.7	60	0.1	1,450
Urinary bladder ^c	3.3	31	0.8	126	1.0	98	0.3	321
Uterine cervix	--	--	--	--	0.6	156	0.2	490
Uterine corpus	--	--	--	--	3.1	32	0.7	148

^aExcludes basal cell and squamous cell skin cancers and in situ cancers except urinary bladder.

^bStatistics are for non-Hispanic Whites.

^cIncludes invasive and in situ cancer cases.

Data source: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.9.2, National Cancer Institute, 2025.

